Latest news with #FIBREConsortium
Yahoo
a day ago
- Business
- Yahoo
Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium's primary goal is to revolutionize the treatment of fibrotic diseases by using advanced imaging biomarkers. The FIBRE (Fibrosis Imaging Biomarker Research & Evaluation) Consortium aims to accelerate biomarker validation and reduce the costs of clinical trials for fibrotic diseases through innovative imaging technologies. Lantheus's contribution includes supplying LNTH-1363S, which is a PET tracer targeting Fibroblast Activation Protein/FAP. FAP is a protein expressed exclusively by activated fibroblasts. A medical professional performing a pulmonary function assessment on a patient. This biomarker, along with Lumina's [⁶⁸Ga]CBP8 PET/MRI tracer for Collagen Type I, will enable the quantification of fibrosis burden and treatment response within weeks, and potentially reduce trial durations by 60% and costs by ~$400 million. Initial studies will focus on Metabolic Dysfunction-Associated Steatohepatitis/MASH, with potential expansion into other fibrotic conditions. Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist in the diagnosis and treatment of heart, cancer, and other diseases. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium's primary goal is to revolutionize the treatment of fibrotic diseases by using advanced imaging biomarkers. The FIBRE (Fibrosis Imaging Biomarker Research & Evaluation) Consortium aims to accelerate biomarker validation and reduce the costs of clinical trials for fibrotic diseases through innovative imaging technologies. Lantheus's contribution includes supplying LNTH-1363S, which is a PET tracer targeting Fibroblast Activation Protein/FAP. FAP is a protein expressed exclusively by activated fibroblasts. A medical professional performing a pulmonary function assessment on a patient. This biomarker, along with Lumina's [⁶⁸Ga]CBP8 PET/MRI tracer for Collagen Type I, will enable the quantification of fibrosis burden and treatment response within weeks, and potentially reduce trial durations by 60% and costs by ~$400 million. Initial studies will focus on Metabolic Dysfunction-Associated Steatohepatitis/MASH, with potential expansion into other fibrotic conditions. Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist in the diagnosis and treatment of heart, cancer, and other diseases. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
20-06-2025
- Business
- Yahoo
Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging
The recent formation of the FIBRE Consortium, a collaboration involving Pfizer and other pharmaceutical partners, aims to pioneer advancements in fibrotic disease management. Alongside this, Pfizer's submission of a New Drug Application for vepdegestrant to treat breast cancer and significant progress in colorectal and prostate cancer therapies were key developments. Over the past month, Pfizer's stock saw a price increase of 4%. The company's performance appeared aligned with market trends amid geopolitical tensions and fluctuations in oil prices, indicating resilience within the broader mixed market conditions. These recent strategic initiatives have likely provided a positive foundation. We've identified 3 possible red flags with Pfizer and understanding the impact should be part of your investment process. Uncover 17 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The developments in Pfizer's strategic initiatives, specifically the formation of the FIBRE Consortium and the submission of the New Drug Application for vepdegestrant, could potentially enhance the company's revenue and earnings forecasts. These projects may strengthen Pfizer's position in the competitive pharmaceuticals landscape, especially as the company intensifies its focus on oncology. However, the ongoing threat of increased competition and reduced utilization of key drugs remain factors that may pressure revenue, possibly mitigating some of the positive impacts from the recent news. Over the past five years, Pfizer's total return, including share price and dividends, was a 1.05% decline, illustrating longer-term challenges despite short-term gains. On a one-year basis, the stock underperformed the US market, which achieved a 10.4% return, indicating some operational hurdles within the company. The recent strategic progress may offer potential relief if executed effectively. The stock's performance, with a recent monthly increase of 4%, places it in a unique position relative to the consensus analyst price target of US$29.24. The current share price of US$24.41 sits at a 22% discount to this target, hinting at potential upside according to more optimistic analysts. In contrast, some bearish analysts set a price target closer to US$24.57, suggesting that expectations are diverse. This disparity in views underscores the importance of closely monitoring how Pfizer's strategic developments influence its future performance and valuation. Jump into the full analysis health report here for a deeper understanding of Pfizer. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
